Figure 4.
Impact of additional CAs and type of BCR-ABL1 transcript on survival outcomes. (A) EFS curves of patients with additional CAs and isolated Ph positivity; 3-year EFS rates from enrollment were 61.8% (95% confidence interval [CI], 46.8-73.7) and 77.8% (95% CI, 51.1-91.0), respectively. (B) OS curves of patients with additional CAs and isolated Ph positivity; 3-year OS rates from enrollment were 73.9% (95% CI, 59.3-83.9) and 100%, respectively. (C) EFS curves of patients with major BCR-ABL1 and minor BCR-ABL1 transcripts; 3-year EFS rates from enrollment were 75.9% (95% CI, 51.4-89.2) and 62.4% (95% CI, 48.4-73.7), respectively. (D) OS curves of patients with major BCR-ABL1 and minor BCR-ABL1 transcripts; 3-year OS rates from enrollment were 90.5% (95% CI, 67.0-97.5) and 76.7% (95% CI, 63.3-85.8), respectively.

Impact of additional CAs and type of BCR-ABL1 transcript on survival outcomes. (A) EFS curves of patients with additional CAs and isolated Ph positivity; 3-year EFS rates from enrollment were 61.8% (95% confidence interval [CI], 46.8-73.7) and 77.8% (95% CI, 51.1-91.0), respectively. (B) OS curves of patients with additional CAs and isolated Ph positivity; 3-year OS rates from enrollment were 73.9% (95% CI, 59.3-83.9) and 100%, respectively. (C) EFS curves of patients with major BCR-ABL1 and minor BCR-ABL1 transcripts; 3-year EFS rates from enrollment were 75.9% (95% CI, 51.4-89.2) and 62.4% (95% CI, 48.4-73.7), respectively. (D) OS curves of patients with major BCR-ABL1 and minor BCR-ABL1 transcripts; 3-year OS rates from enrollment were 90.5% (95% CI, 67.0-97.5) and 76.7% (95% CI, 63.3-85.8), respectively.

Close Modal

or Create an Account

Close Modal
Close Modal